Background and objectives It has been suggested that reduced estimated GFR (eGFR) among older adults does not necessarily reflect a pathologic phenomenon.
Introduction
The prevalence of chronic kidney disease (CKD) is markedly higher at older ages (1) (2) (3) . However, controversy exists as to whether CKD is a risk factor for adverse outcomes among older adults (4, 5) . Two large studies found that moderate reductions in eGFR were not associated with increased mortality among older adults (i.e., Ն 60 years of age in one study and Ն65 years in the other study) (6 -8) . In contrast, in meta-analyses of general population and high-risk cohorts conducted by the Chronic Kidney Disease Prognosis Consortium (CKD-PC), an association was present between eGFR Ͻ60 ml/min per 1.73 m 2 and increased all-cause and cardiovascular mortality among adults Ͻ65 years of age and their counterparts Ն65 years of age (9, 10) .
Until recently, there were limited published data on the association of albuminuria with mortality across the full range of age including older adults. In one study of patients with diabetes mellitus from the Veterans Administration Medical Centers, albumin-tocreatinine ratio (ACR) levels Ն30 mg/g were associated with all-cause mortality among adults Ն75 years of age (11) . Additionally, in general population and high-risk cohorts included in the CKD-PC, higher levels of albuminuria were associated with increased all-cause mortality for adults Ͻ65 and Ն65 years of age (9, 10) .
Using age-specific estimated GFR (eGFR) cutpoints for defining CKD in the National Kidney Foundation guidelines has been proposed (12) . Also, most age-specific analyses of eGFR and ACR with outcomes have stratified the population at 65 years of age and have not investigated outcomes associated with reduced eGFR and albuminuria at older ages. Therefore, we evaluated the age-specific association between eGFR and albuminuria levels with all-cause mortality across a wide age distribution among participants in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. The REGARDS study enrolled U.S. adults Ն45 years of age, including many participants older than 80 years of age, African Americans, and women.
Study Population and Methods

Study Participants
The REGARDS study is a population-based investigation of stroke incidence among U.S. adults Ն45 years of age (13) . The study was designed to oversample African Americans, residents of the stroke-belt region of the United States, and to provide approximate equal representation of men and women. Overall, 30,239 African-American and white U.S. adults were enrolled between January 2003 and October 2007. Participants receiving hemodialysis (n ϭ 54) or those without urinary albumin and creatinine (n ϭ 1485) or serum creatinine (n ϭ 958) measurements, those without follow-up data (n ϭ 498), or those who were missing covariable information (n ϭ 2894) were excluded, leaving 24,350 participants with complete data for the analysis presented here. Compared with participants included in this analysis, those excluded for missing serum creatinine or urinary albumin and creatinine were older (65.6 versus 64.8 years) and more likely to be women (64% versus 54%) and African American (53% versus 40%). However, participants excluded for missing covariables were not markedly different from those included in this analysis with respect to eGFR and ACR levels. The institutional review boards governing research in human subjects at the participating centers approved the REGARDS study protocol, and all participants provided informed consent.
Data Collection
The REGARDS study data were collected through interview-and self-administered questionnaires and during an in-home study visit. The following were obtained via selfreport: age, race, gender, education, physical activity, annual household income, cigarette smoking, self-rated health, antihypertensive medication use, and a prior diagnosis of coronary heart disease, stroke, atrial fibrillation, and diabetes mellitus. The in-home examination included clinical measurements, a pill bottle review, an electrocardiogram, and the collection of a fasting blood sample and urine sample. BP was measured two times, and waist circumference was measured midway between the lowest rib and the iliac crest with the participant standing.
Laboratory Measures
Serum creatinine assays were performed at the University of Vermont and calibrated with an isotope dilution mass spectroscopic standard (14) . The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used to calculate eGFR (15) . Urinary albumin and creatinine were measured at the Department of Laboratory Medicine and Pathology at the University of Minnesota using the BN ProSpec Nephelometer from Dade Behring (Marburg, Germany) (16) . C-reactive protein was measured using a high-sensitivity, particle-enhanced immunonepholometric assay, and levels Ն2 mg/L were defined as elevated. Total and HDL cholesterol and triglycerides were measured, and LDL cholesterol was calculated using the Freidewald equation (17) . Diabetes mellitus was defined as fasting glucose Ն126 mg/dl, nonfasting glucose Ն200 mg/ dl, or self-report of a prior diagnosis with current use of insulin or antidiabetes medication.
Outcome Assessment-All-Cause Mortality
Mortality, subsequent to the REGARDS study in-home examination and through September 30, 2010, was assessed through contact with proxies provided by the participant upon recruitment or during follow-up. If a proxy reported a participant had died, an interview was conducted with the next of kin listed on study forms. The REGARDS study confirmed dates of death through the Social Security death index, death certificates, or the national death index. Follow-up time was recorded as the number of days from the baseline in-home visit to a participant's confirmed date of death or their last REGARDS study telephone contact before September 30, 2010 for nondeceased participants.
Statistical Analyses
Characteristics of the REGARDS study population included in this analysis were calculated by age group (45 to 59.9, 60 to 69.9, 70 to 79.9, and Ն80 years), within each age group by level of eGFR (Ն60, 45 to 59.9, and Ͻ45 ml/min per 1.73 m 2 ), and separately by level of ACR (Ͻ10, 10 to 29.9, 30 to 299.9, and Ն300 mg/g). All-cause mortality rates were calculated by age group and level of eGFR and by age group and level of ACR. Using age-stratified Cox proportional hazard models, the hazard ratios for all-cause mortality associated with eGFR and ACR levels, separately, were calculated. Initial models included adjustment for age, race, gender, and region of residence with subsequent models including additional adjustment for education, physical activity, income, current smoking, general health status, waist circumstance, systolic BP, diastolic BP, antihypertensive medicine use, diabetes mellitus, LDL cholesterol, HDL cholesterol, statin use, elevated C-reactive protein, history of coronary heart disease, stroke, atrial fibrillation, and ACR (for the model of eGFR and mortality) or eGFR (for the model of ACR and mortality). Additionally, for each age group separately, the joint effect of eGFR and ACR on all-cause mortality was determined using Cox proportional hazard models with eGFR Ն60 ml/min per 1.73 m 2 and ACR Ͻ10 mg/g serving as the referent group. Within each age group, trends in mortality rates and hazard ratios for mortality across eGFR and ACR categories were calculated by assigning the median eGFR or ACR value for participants in the category and modeling these variables as continuous independent variables. Two sensitivity analyses were conducted. First, the multivariable adjusted hazard ratios for all-cause mortality associated with ACR levels were determined by age group for men and women, separately, and participants with and without diabetes mellitus, separately. Second, we calculated age-specific hazard ratios for all-cause mortality associated with urinary albumin concentration rather than ACR. Multiplicative interaction between eGFR and age group, and ACR and age group, was assessed by comparing the log likelihoods for models with and without interaction terms for age group by eGFR categories and age group by ACR categories. Additive interaction was assessed via the relative excess risk due to interaction using the method described by Li and Chambless (18) . SAS version 9.2 (SAS Institute, Cary, NC) was used for all analyses.
Results
Participant Characteristics
Participant characteristics are presented by age grouping in Table 1 , by age grouping and eGFR level in Supplemental Table 1 , and age grouping and ACR level in Supplemental Table 2 . Within each age grouping, the prevalence of ACR levels Ն30 mg/g was higher at progressively lower eGFR levels. Also, the prevalence of eGFR Ͻ60 ml/min per 1.73 m 2 was higher at higher ACR levels within each age grouping.
Association of Reduced eGFR with Mortality by Age
The number of deaths among REGARDS study participants through September 30, 2010 are provided in Supplemental Table 3 . There was a graded increase in crude mortality rates at lower eGFR levels within each age group ( Figure 1 and Supplemental Table 4 ). Within each age grouping, the age, race, gender, and geographic region of residence adjusted hazard ratio for mortality increased progressively at lower eGFR levels ( Table 2 ). The hazard ratios were attenuated, but the overall pattern of higher mortality at lower eGFR levels remained present after further multivariable adjustment. Neither multiplicative nor additive interaction between age and eGFR levels on all-cause mortality were present (each test for P interaction Ͼ0.1).
Association of Elevated ACR with Mortality by Age
Within each age grouping, the crude mortality rate increased at higher ACR levels ( Figure 2 and Supplemental Table 5 ). After adjustment for age, race, gender, and geographic region of residence, there was a graded relationship between higher ACR levels and higher hazard ratios for all-cause mortality within each age grouping (Table 3) . The magnitude of the hazard ratios was similar within each age grouping. This pattern remained present after further multivariable adjustment. Neither multiplicative nor additive interaction between age and ACR levels on all-cause mortality was present (each test for P interaction Ͼ0.1). Additionally, higher urinary albumin concentration was associated with increased hazard ratios for all-cause mortality in each age group (Supplementary Table 6 ). When stratified by gender, the association between higher ACR levels and increased hazard ratios for all-cause mortality was similar within each age group for men and women (Supplementary Tables 7 and 8 ). Also, higher ACR levels were associated with increased multivariable ad- Numbers in table are mean (standard deviation) or percentage except for urine albumin concentration and urine creatinine concentration, which are median (25th to 75th percentiles). hsCRP, high sensitivity C-reactive protein; CHD, coronary heart disease; ACR, urinary albumin-to-creatinine ratio; eGFR, estimated GFR.
justed hazard ratios for mortality within each age group for participants with and without diabetes ( Table 4) .
Joint Effect of eGFR and ACR on Mortality by Age
The age-specific joint effect of eGFR and ACR levels on all-cause mortality are presented in Table 5 . For each age grouping, higher hazard ratios for mortality were present at lower eGFR levels within each ACR level except 10 to 29.9 mg/g for participants 45 to 59.9 years of age and Ն300 mg/g among participants 70 to 79.9 and Ն80 years of age. When stratified by level of eGFR, higher age, race, gender, and geographic region of residence adjusted hazard ratios for mortality were present at higher ACR levels for participants 60 to 69.9, 70 to 79.9, and Ն80 years of age. Among participants 45 to 59.9 years of age, higher hazard ratios at higher ACR levels were present among individuals with eGFR levels Ն60 ml/min per 1.73 m 2 but not for their peers with eGFR levels of 45 to 59.9 or Ͻ45 ml/min per 1.73 m 2 .
Discussion
In this population-based study of U.S. adults, reduced eGFR and elevated ACR were associated with higher rates of all-cause mortality in all age groups, including in individuals Ն80 years of age. A substantially increased risk for all-cause mortality was present for individuals with a moderate reduction in eGFR (45 and 59.9 ml/min per 1.73 m 2 ) and for ACR levels considered within the normal rage (10 to 29.9 mg/g). These results were robust to multivariable adjustment and remained present when the joint effect of eGFR and ACR was assessed.
The finding that reduced eGFR is associated with allcause mortality regardless of age differs from a prior analysis of U.S. veterans (6). Among U.S. veterans Ն65 years of age in the prior study, the annual mortality rate was only approximately 10% higher among those with eGFR of 50 to 59 versus Ն60 ml/min per 1.73 m 2 , which was attenuated after adjustment. However, in the meta-analysis of general Table 4 for all-cause mortality rates with 95% CIs. Table 5 for all-cause mortality rates with 95% CIs.
population studies conducted by the CKD-PC, reduced eGFR was associated with increased hazard ratios for allcause mortality among individuals Ͻ65 and Ն65 years of age. The hazard ratio comparing eGFR levels of 45 to 95 ml/min per 1.73 m 2 was 2.14 (95% confidence interval [CI]: 1.56 to 2.92) and 1.60 (95% CI: 1.46 to 1.75) for individuals Ͻ65 and Ն65 years of age, respectively (9) .
Although the hazard ratios for mortality associated with increased ACR were similar within each age group, consistent with the CKD-PC data cited above, the hazard ratios associated with an eGFR of 45 to 59.9 ml/min per 1.73 m 2 were closer to the null for the older compared with younger age groups in the study presented here. However, the comparison of the magnitude of hazard ratios across subgroups of the population with different baseline risk for outcomes should be undertaken cautiously. As described by Howard, there may be a natural tendency to infer that a smaller hazard ratio among older adults means that a risk factor has decreased importance in this subgroup (19) . In fact, a smaller relative increase in a group Data presented as multivariable adjusted HR (95% CI). Multivariable adjusted includes age, gender, race, region, education, physical activity, income, current smoking, general health status, waist circumstance, systolic BP, diastolic BP, antihypertensive medicine use, LDL cholesterol, HDL cholesterol, statin use, C-reactive protein Ն 2 mg/L, history of coronary heart disease, selfreported stroke, self-reported or electrocardiogram evidence of atrial fibrillation, and estimated GFR. HR, hazard ratio.
with a higher base mortality rate may have a higher public health effect. As noted in Figures 1 and 2 , despite lower hazard ratios for eGFR levels of 45 to 59.9 versus Ն60 ml/min per 1.73 m 2 at older age, the absolute differences in mortality rates by level of eGFR and ACR were similar across age groups. Additionally, even after multivariable adjustment for potential confounders, reduced eGFR and ACR levels were associated with increased hazard ratio for mortality, and additive interaction between age and eGFR and age and ACR with mortality was not present.
Higher levels of albuminuria have been reported to be associated with increased mortality in prior studies of older adults with diabetes mellitus and in the general population (11, 20) . O'Hare and colleagues reported ACR levels Ն30 mg/g to be associated with increased mortality, regardless of age, among U.S. veterans with diabetes mellitus (11) . Also, the hazard ratio for all-cause mortality associated with higher ACR levels (42.5 versus 5.1 mg/g) was similar for adults Ͻ65 years of age (1.49, 95% CI: 1.40 to 1.59) and Ն65 years of age (1.52, 95% CI: 1.45 to 1.61) in the CKD-PC (9) . The study presented here extends the findings from U.S. veterans and the CKD-PC in several important ways. Most notably, all-cause mortality was investigated in narrow age bands (i.e., 45 to 59, 60 to 69, 70 to 79, and Ն80 years of age) in this study. Such data were not reported by the CKD-PC. Compared with the study of U.S. veterans, REGARDS enrolled participants with and without diabetes mellitus and higher ACR was associated with increased hazard ratios for mortality in each of these subgroups. Results were consistent when urine albumin concentration was used in place of ACR, suggesting that the association of ACR with all-cause mortality is not due to reduced urine creatinine concentration.
The use of age-specific cutpoints (e.g., eGFR Ͻ 60 ml/ min per 1.73 m 2 for adults Ͻ65 years of age and Ͻ45 ml/min per 1.73 m 2 for adults Ն65 years of age) for defining reduced eGFR has been suggested (4). Additionally, incorporation of ACR level for diagnosing CKD in older adults has also been proposed (21) . The argument for age-specific eGFR cutpoints is based partially on the large number of older adults with reduced eGFR but without evidence of kidney damage (5). However, among individuals with eGFR levels of 45 to 59.9 ml/min per 1.73 m 2 in this study, the proportion with ACR Ն30 mg/g was higher for those Ն80 years of age (33.0%) than their younger counterparts (24.4%, 27.9%, and 25.0% for participants 70 to 79.9, 60 to 69.9, and 45 to 59.9 years of age, respectively). Furthermore, within each age group, a graded relationship between lower levels of eGFR and increased mortality was present among individuals with ACR Ͻ 10 mg/g. Beyond these potential implications for CKD diagnosis, the current findings highlight the importance of eGFR and ACR for assessing prognosis in older adults. Although among the "oldest old" a disease-oriented focus on diagnosis becomes less important, eGFR and ACR may serve as important tools for risk assessment, informing broader clinical decisions as part of individually tailored, patient-oriented care plans. Further studies are needed to understand the effect of identifying older adults with reduced eGFR and increased ACR for individual patients and from a public health standpoint; however, the data presented here do not support the need for age-specific eGFR or ACR cutpoints.
The results of this study should be interpreted within the context of certain limitations. Measurements of eGFR and ACR were obtained on a single occasion. Many individuals with high ACR levels may not have persistent albuminuria (22) . Although REGARDS study visits were conducted in the morning, the spot urine samples collected were not necessarily obtained from a first void. Another limitation is that the only outcome was all-cause mortality. End-stage renal disease is being identified in the REGARDS study; however, not enough cases have occurred to date to calculate reliable estimates by age and eGFR or ACR level. Although we adjusted for several potential confounders, the possibility of residual confounding remains present. Despite these limitations, the study presented here has many strengths. Most notable are the population-based sample of the REGARDS study, the measurement of serum creatinine and urinary albumin and creatinine following a standardized protocol, and the active follow-up of participants for all-cause mortality. Additionally, there were many REGARDS study participants Ն80 years of age with complete data available for the analysis presented here. This large sample size allowed for the estimation of allcause mortality by the joint effect of eGFR and ACR levels.
In conclusion, this study identified a strong relationship between reduced eGFR and higher levels of ACR with all-cause mortality across a broad age range, including adults Ն80 years old. Despite a decline in the hazard ratio for all-cause mortality associated with reduced eGFR and higher ACR with age, the difference in absolute risk for all-cause mortality associated with reduced eGFR and increased ACR remained constant across age groupings. Future studies are needed to evaluate the association of reduced eGFR and albuminuria with other outcomes (e.g., cardiovascular disease, end-stage renal disease, and geriatric conditions such as falls, low mobility, and functional decline) across the full range of age. In the interim, these data suggest that age-specific eGFR or ACR cutpoints for identifying high risk for mortality are not needed and may result in the underappreciation of the excess all-cause mortality risk associated with reduced eGFR and increased ACR for all age groups including individuals Ն80 years of age.
